Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Salmonella-associated acute pancreatitis in a patient with ulcerative colitis
Publication Year: 2025 Source: Rev Esp Enferm Dig PMID: 38235692
Inflammatory bowel disease is a known risk factor for enteric infections such as Salmonella. This infection can affect almost all major organs. Acute Salmonella pancreatitis is a rare complication. This is the case of a 61-year-old man with ulcerative colitis who developed acute pancreatitis complicating Salmonella infection.
Secondary orofacial granulomatosis due to Crohn's disease
Publication Year: 2025 Source: Rev Esp Enferm Dig PMID: 38235750
We report the case of a 34-year-old female with Crohn's disease (CD), was treated with infliximab and ileocecal resection after failure to anti-TNF. She started adalimumab for postoperative recurrence for two years, with sustained clinical and endoscopic remission. She presents with a 1.5-year history of a persistent, asymptomatic, rubbery swelling …
Can dysmetabolic comorbidities carry hepatic fat accumulation in patients with inflammatory bowel diseases?
Publication Year: 2025 Source: Minerva Gastroenterol (Torino) PMID: 38240685
No Abstract
Performance of ASCVD Risk Prediction Models in Individuals With Inflammatory Bowel Disease: A UK Biobank Study
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 38241516 DOI: 10.1093/ibd/izae007
No Abstract
Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis
Publication Year: 2025 Source: J Crohns Colitis PMID: 38066679
BACKGROUND: Filgotinib is a small molecule with preferential inhibition of Janus kinase type 1, approved for the treatment of ulcerative colitis in Scotland in May 2022. We present the first real-world experience on its use in clinical practice. METHODS: In this retrospective, observational, cohort study we assessed patients with active …
Improvement of inflammatory bowel disease by lactic acid bacteria-derived metabolites: a review
Publication Year: 2025 Source: Crit Rev Food Sci Nutr PMID: 38078699 DOI: 10.1080/10408398.2023.2291188
Lactic acid bacteria (LAB) plays a crucial role in the establishment and maintenance of host health, as well as the improvement of some diseases. One of the major modes is the secretion of metabolites that may be intermediate or end products of the LAB's metabolism. In this review, we summarized …
A combined ligand-based and structure-based in silico molecular modeling approach to pinpoint the key structural attributes of hydroxamate derivatives as promising meprin β inhibitors
Publication Year: 2025 Source: J Biomol Struct Dyn PMID: 38165455
No Abstract
Construction of identity in individuals with inflammatory bowel disease across the lifespan
Publication Year: 2025 Source: Psychol Health PMID: 38173135 DOI: 10.1080/08870446.2023.2299243
Inflammatory bowel disease (IBD) is a chronic illness that affects 10 million individuals worldwide; however, Canada has the highest rates of IBD per capita in the world. Presently, 0.7% of Canadians are diagnosed with IBD, which is expected to rise to 1% by 2030. Disease onset is typically between the …
Integrated Bioinformatics Analysis and Target Drug Prediction of Inflammatory Bowel Disease Co-existent Diabetes Mellitus
Publication Year: 2025 Source: Curr Comput Aided Drug Des PMID: 38173213 DOI: 10.2174/0115734099282247231211111219
INTRODUCTION: Inflammatory bowel disease (IBD) has become one of the public problems worldwide and its incidence rate is increasing year by year. Its concomitant disease i.e. diabetes mellitus (DM) has attracted more and more attention due to DM altering the progression of IBD and leading to long periods of intermittent …
Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease
Publication Year: 2025 Source: Clin Gastroenterol Hepatol PMID: 38199301 DOI: 10.1016/j.cgh.2023.12.029
BACKGROUND & AIMS: Limited data are available on the consequences of prenatal exposure to vedolizumab and ustekinumab. We aimed to compare the safety of vedolizumab and ustekinumab with that of anti-tumor necrosis factor (TNF) in pregnant women with inflammatory bowel diseases (IBD). METHODS: Using nationwide, comprehensive data of the EPI-MERES …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide